Literature DB >> 24366072

Heart failure in 2013: Continue what we are doing to treat HF, but do it better.

Jay N Cohn1.   

Abstract

In 2013, clinical trials in heart failure focused on drugs and devices that might improve treatment of symptomatic patients beyond standard therapy. None achieved this aim. Therefore, future efforts should emphasize increased adherence to current, evidence-based therapy, and trials might better address efforts to prevent, rather than treat, heart failure.

Entities:  

Mesh：

Year:  2013        PMID： 24366072     DOI： 10.1038/nrcardio.2013.212

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.

Authors:  Frank Ruschitzka; William T Abraham; Jagmeet P Singh; Jeroen J Bax; Jeffrey S Borer; Josep Brugada; Kenneth Dickstein; Ian Ford; John Gorcsan; Daniel Gras; Henry Krum; Peter Sogaard; Johannes Holzmeister
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition.

Authors:  J N Cohn
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

4.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

5.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

6.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.

Authors:  Frank Edelmann; Rolf Wachter; Albrecht G Schmidt; Elisabeth Kraigher-Krainer; Caterina Colantonio; Wolfram Kamke; André Duvinage; Raoul Stahrenberg; Kathleen Durstewitz; Markus Löffler; Hans-Dirk Düngen; Carsten Tschöpe; Christoph Herrmann-Lingen; Martin Halle; Gerd Hasenfuss; Götz Gelbrich; Burkert Pieske
Journal:  JAMA       Date:  2013-02-27       Impact factor: 56.272

7.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

8.  Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.

Authors:  Wojciech Kosmala; David J Holland; Aleksandra Rojek; Leah Wright; Monika Przewlocka-Kosmala; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2013-07-31       Impact factor: 24.094

9.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.

Authors:  Horng H Chen; Kevin J Anstrom; Michael M Givertz; Lynne W Stevenson; Marc J Semigran; Steven R Goldsmith; Bradley A Bart; David A Bull; Josef Stehlik; Martin M LeWinter; Marvin A Konstam; Gordon S Huggins; Jean L Rouleau; Eileen O'Meara; W H Wilson Tang; Randall C Starling; Javed Butler; Anita Deswal; G Michael Felker; Christopher M O'Connor; Raphael E Bonita; Kenneth B Margulies; Thomas P Cappola; Elizabeth O Ofili; Douglas L Mann; Víctor G Dávila-Román; Steven E McNulty; Barry A Borlaug; Eric J Velazquez; Kerry L Lee; Monica R Shah; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield
Journal:  JAMA       Date:  2013-12-18       Impact factor: 56.272
  9 in total
  6 in total

Review 1.  Management of atrial fibrillation in bradyarrhythmias.

Authors:  Giuseppe Boriani; Luigi Padeletti
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

Review 2.  Epidemiology and aetiology of heart failure.

Authors:  Boback Ziaeian; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2016-03-03       Impact factor: 32.419

Review 3.  A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart.

Authors:  Satsuki Fukushima; Shigeru Miyagawa; Yoshiki Sakai; Yoshiki Sawa
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

Review 4.  Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart.

Authors:  Shigeru Miyagawa; Satsuki Fukushima; Yukiko Imanishi; Takuji Kawamura; Noriko Mochizuki-Oda; Shigeo Masuda; Yoshiki Sawa
Journal:  Curr Gene Ther       Date:  2016       Impact factor: 4.391

5.  Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy.

Authors:  Shigeru Miyagawa; Satoshi Kainuma; Takuji Kawamura; Kota Suzuki; Yoshito Ito; Hiroko Iseoka; Emiko Ito; Maki Takeda; Masao Sasai; Noriko Mochizuki-Oda; Tomomi Shimamoto; Yukako Nitta; Hiromi Dohi; Tadashi Watabe; Yasushi Sakata; Koichi Toda; Yoshiki Sawa
Journal:  Front Cardiovasc Med       Date:  2022-08-16

6.  Laminin-221 Enhances Therapeutic Effects of Human-Induced Pluripotent Stem Cell-Derived 3-Dimensional Engineered Cardiac Tissue Transplantation in a Rat Ischemic Cardiomyopathy Model.

Authors:  Takaaki Samura; Shigeru Miyagawa; Takuji Kawamura; Satsuki Fukushima; Jun-Ya Yokoyama; Maki Takeda; Akima Harada; Fumiya Ohashi; Ryoko Sato-Nishiuchi; Toshihiko Toyofuku; Koichi Toda; Kiyotoshi Sekiguchi; Yoshiki Sawa
Journal:  J Am Heart Assoc       Date:  2020-08-12       Impact factor: 5.501
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.